KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBIT Margin (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of EBIT Margin data on record, last reported at 33.19% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 428.0% year-over-year to 33.19%; the TTM value through Dec 2025 reached 42.63%, up 2914.0%, while the annual FY2025 figure was 42.63%, 2914.0% up from the prior year.
  • EBIT Margin reached 33.19% in Q4 2025 per RIGL's latest filing, down from 40.91% in the prior quarter.
  • Across five years, EBIT Margin topped out at 60.09% in Q2 2025 and bottomed at 156.92% in Q1 2022.
  • Average EBIT Margin over 5 years is 18.1%, with a median of 7.33% recorded in 2023.
  • The widest YoY moves for EBIT Margin: up 10900bps in 2022, down -20846bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 104.94% in 2021, then skyrocketed by 104bps to 4.05% in 2022, then surged by 35bps to 5.49% in 2023, then surged by 426bps to 28.92% in 2024, then increased by 15bps to 33.19% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 33.19% in Q4 2025, 40.91% in Q3 2025, and 60.09% in Q2 2025.